COMPASS PATHWAYS PLC Deferred Offering Costs
COMPASS PATHWAYS PLC (CMPS) had Deferred Offering Costs of $228.00 thousand as of 2021-09-30, per its 6-K filed 2021-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2021-11-09
- 2021-09-30: Deferred Offering Costs $228.00K.
- 2020-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-09-30 | $228.00K 6-K · filed 2021-11-09 |
| 2020-12-31 | $0.00 6-K · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |